Inhibikase Therapeutics Inc（IKT）股票分析

AI 分析 of Inhibikase Therapeutics Inc (IKT)

持有

Inhibikase Therapeutics Inc is currently not a strong buy. The stock is trading at $1.54, which is close to its 52-week low of $1.39 and significantly below its 52-week high of $2.61. The RSI is at 34.034, indicating that the stock is in oversold territory, which could suggest a potential rebound. However, the forward P/E ratio is 0, indicating no expected earnings growth in the near term. Additionally, the company has reported consistent net losses, with a net income of -$19,591,231 in Q2 2026, raising concerns about its profitability. The main risk is the ongoing negative earnings trend, as evidenced by the EPS of -0.11 for the last quarter, which was worse than the market's expectations. Overall, while there may be a potential for recovery, the current financial instability suggests a cautious approach.

估值指標

Inhibikase Therapeutics Inc（IKT）目前預期本益比為 0.00，5 年平均預期本益比為 -2.42。

預期本益比

高估

5 年均值 P/E

-2.42

目前P/E

0.00

高估

-0.53

低估

-4.32

預期 EV/EBITDA

嚴重低估

5 年均值 EV/EBITDA

0.00

目前EV/EBITDA

0.00

高估

0.00

低估

0.00

預期股價營收比

嚴重高估

5 年均值 P/S

150.84

目前P/S

826.05

高估

463.07

低估

-161.39

Alphio AI 對 IKT 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%IKT

$2.41

情境價格

基

基準

基準 · 50%IKT

$2.22

情境價格

悲

悲觀

悲觀 · 25%IKT

$2.07

情境價格

持有 IKT 的大戶

B

Blackstone Alternative Investment Advisors LLC

+ 持有IKT

-0.88%

3個月報酬率

S

Soleus Capital Management, L.P.

+ 持有IKT

-7.34%

3個月報酬率

A

ADAR1 Capital Management, LLC

+ 持有IKT

-14.25%

3個月報酬率

IKT 常見問題 —— 由 Alphio AI 解答

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Inhibikase Therapeutics Inc is currently not a strong buy. The stock is trading at $1.54, which is close to its 52-week low of $1.39 and significantly below its 52-week high of $2.61. The RSI is at 34.034, indicating that the stock is in oversold territory, which could suggest a potential rebound. However, the forward P/E ratio is 0, indicating no expected earnings growth in the near term. Additionally, the company has reported consistent net losses, with a net income of -$19,591,231 in Q2 2026, raising concerns about its profitability. The main risk is the ongoing negative earnings trend, as evidenced by the EPS of -0.11 for the last quarter, which was worse than the market's expectations. Overall, while there may be a potential for recovery, the current financial instability suggests a cautious approach.